Connection

HANA EL SAHLY to Clinical Trials as Topic

This is a "connection" page, showing publications HANA EL SAHLY has written about Clinical Trials as Topic.
Connection Strength

0.215
  1. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity. Expert Rev Vaccines. 2010 Oct; 9(10):1135-41.
    View in: PubMed
    Score: 0.059
  2. Clinical data on Fluarix: an inactivated split seasonal influenza vaccine. Expert Rev Vaccines. 2008 Aug; 7(6):713-9.
    View in: PubMed
    Score: 0.051
  3. Pandemic H5N1 influenza vaccine development: an update. Expert Rev Vaccines. 2008 Mar; 7(2):241-7.
    View in: PubMed
    Score: 0.050
  4. Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial. JAMA Netw Open. 2022 06 01; 5(6):e2215984.
    View in: PubMed
    Score: 0.033
  5. Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans. Clin Vaccine Immunol. 2016 Apr; 23(4):326-38.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.